Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 4/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372934 | 0.80 | MAPT (0.53) | ASIC1 | |
| SCHEMBL5398740 | 0.79 | GABRG2 (0.44) | GABRG2GABRB3GABRA5GABRA3NPY5R | |
| SCHEMBL5382808 | 0.79 | GABRG2 (0.43) | GABRG2GABRB3GABRA5GABRA3NPY5R | |
| SCHEMBL13975286 | 0.77 | XDH (0.49) | IDO1GRM5CLK4CTSSCTSK | |
| SCHEMBL5393535 | 0.75 | ASIC1 (0.43) | GABRG2GABRB3GABRA5GABRA3ASIC1 | |
| SCHEMBL17489532 | 0.75 | BRD4 (0.48) | IDO1GRM5CLK4 | |
| SCHEMBL8545474 | 0.75 | MAPT (0.52) | NPY5RCLK4EGLN2 | |
| SCHEMBL31395062 | 0.75 | GABRG2 (0.65) | GABRG2GABRB3GABRA5GABRA3NPY5R | |
| SCHEMBL20491327 | 0.75 | GABRG2 (0.65) | GABRG2GABRB3GABRA5GABRA3NPY5R | |
| SCHEMBL22307603 | 0.73 | ALDH1A1 (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7295376-B2 | Pseudo cross-link type resin composition, molding material, sheet or film, and optical element obtained therefrom | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20060264474-A1 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2006-11-23 | — | — | US | disclosed |
| US-20050038194-A1 | Pseudo cross-link type resin composition, molding material, sheet or film, and optical element obtained therefrom | YAMANAKA TETSURO (JP) | 2005-02-17 | — | — | US | disclosed |
| WO-2004089911-A1 | PYRAZOLE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS USEFUL IN THE TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
| US-6767967-B2 | FLEXIBILITY; HYDROGEN BONDED BLEND | HITACHI CHEMICAL CO., LTD. (JP) | 2004-07-27 | — | — | US | disclosed |
| US-20030232923-A1 | Pseudo cross-link type resin composition, molding material, sheet or film, and optical element obtained therefrom | HITACHI CHEMICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264474-A1 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | GABRG2 588/4885GABRB3 154/4885GABRA5 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.